Heregulin-mediated activation of HER4 initiates receptor cleavage (releasing an 80-kDa HER4 intracellular domain, s80 HER4 , containing nuclear localization sequences) and results in G 2 -M delay by unknown signaling mechanisms. We report herein that s80
Introduction
Cell cycle progression involves programming signals that drive proliferation and checkpoint mechanisms that limit cell cycle progression. Progression through mitotic checkpoints requires the proteolytic degradation of certain key regulatory proteins, mediated by the anaphase-promoting complex/cyclosome (APC/C), a multisubunit ubiquitin ligase that catalyzes the attachment of polyubiquitin chains onto substrates (1, 2) , signaling their destruction by the 26S proteasome. Substrate specificity of APC/ C is conferred by its association with coactivators, Cdc20 and Cdh1, each acting as a bridge between the substrate and APC/C. APC/C recognizes small motifs called D-boxes, A-boxes, or KEN boxes. The D-box bears the sequence RXXLXXXXN/D/E (with X being any amino acid) and is found in many proteins ubiquitinated by APC/C [e.g., cyclin B, polo-like kinase, and securin (3) (4) (5) (6) ]. To date, these motifs have not been reported in cell surface receptors. We report herein the presence of a functional D-box motif in the ErbB4/HER4 receptor tyrosine kinase (RTK).
The HER/ErbB family of RTKs consists of four members: HER1/ ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4. Whereas HER1, HER2, and HER3 each contribute to aggressive tumor formation (7, 8) , HER4 signaling may impair cellular proliferation of human breast cells and promote differentiation (9) (10) (11) (12) (13) . In breast cancers, HER4 expression correlates with more differentiated tumor grade, longer survival, and positive prognostic indicators [estrogen receptor (ER) expression and decreased bromodeoxyuridine incorporation (14) (15) (16) (17) (18) (19) (20) ]. HER4 is required for heregulin-mediated growth inhibition in human breast cancer cell lines (9) via delayed progression of cells through late G 2 or early mitosis (21) .
Each of the ErbB receptors has been reported to translocate to the nucleus. For example, HER4 has been detected in the nuclei of breast cancer cells and normal human and mouse mammary tissue (15, 18, (22) (23) (24) (25) . Unlike HER1, HER2, and HER3, which translocate to the nucleus as full-length receptors, only a proteolytically derived intracellular domain of HER4, with a constitutively active kinase domain, becomes nuclear (26) (27) (28) (29) . Recent work shows that one HER4 isoform, JMa, undergoes a ligand-dependent, sequential HER4 proteolytic process. First, the extracellular domain of HER4 (JMa) is cleaved by tumor necrosis a-converting enzyme followed by a transmembrane g-secretase cleavage, which releases the soluble 80-kDa cytoplasmic domain (s80 HER4 ) into the cytosol (30) (31) (32) (33) (34) (35) (36) . Once liberated, s80 HER4 exhibits nuclear-cytoplasmic shuttling. In this report, we examine nuclear s80 HER4 regulation and show that proteolytic generation of s80 HER4 from full-length HER4 was required for HER4-mediated growth inhibition, resulting in growth inhibition via a delay in the G 2 -M phase of the cell cycle. We identified a D-box motif within s80 HER4 that directs APC/Cmediated s80 HER4 degradation during mitosis. Mutation of the HER4 D-box motif stabilized s80 HER4 and increased growth inhibition in response to HER4 or s80 HER4 both in cell culture and in tumor cells in vivo. The pLXSN vectors expressing human HER4, HER4   KD   , and  HER4 V675A and the pcDNA4/TO vectors expressing s80 HER4 and s80 KD are described elsewhere (21, 37) . D-box sequence point mutations in pcDNA4/ TO-s80 and pLXSN-HER4 were done with the primer 5 ¶-TATTCAGGGTGATGATCc TATGAAGa TTCCCAGTCCAAATGAC [lowercase italicized nucleotides represent incorporated mutations; QuikChange Site-Directed Mutagenesis kit (Stratagene)].
Materials and Methods

Plasmids.
Cell culture and transfection. HeLa-TRex cells (Invitrogen), referred to as HeLa-rtTA cells, were cultured according to the manufacturer's protocol, transfected with Fugene6 (Roche), and selected with zeocin (5 Ag/mL; Invitrogen) or G418 (400 Ag/mL). Where indicated, cells were cultured in serum-free DMEM F heregulin h1 (HRG; 10 ng/mL; Genentech), tetracycline (2 Ag/mL), nocodazole (50 ng/mL), or hydroxyurea (10 mmol/L; each from Sigma-Aldrich). Cells synchronized in nocodazole were collected by shake off, pelleted by centrifugation, resuspended in medium containing 10% serum F cycloheximide (Sigma-Aldrich), tetracycline, or HRG, where indicated, and then replated. Where indicated, cells were transiently transfected with short interfering RNA (siRNA) sequences directed against the human APC2 gene using siRNA transfection reagent (Santa Cruz Biotechnology). HC11, MCF-10A, and MDA-MB-453 cells expressing green fluorescent protein (GFP) and GFP-tagged s80 HER4 have been described (38) .
Western blot analysis and immunoprecipitation. Membrane and cytosolic extracts were prepared as described previously (37) . Whole-cell extracts were prepared as described previously (21) . HER4 was immunoprecipitated with a-HER4 Ab-132 or antibodies against Cdc20, APC4 (Santa Cruz Biotechnology), or cyclin B1 (Labvision NeoMarkers) and protein A-agarose or protein A/G+ agarose beads (Santa Cruz Biotechnology). Immunoprecipitates were analyzed by immunoblotting using antibodies GFP, APC4, APC2 (Santa Cruz Biotechnology), cyclin B, or HER4 (Lab Vision NeoMarkers) as described previously (21) .
Fluorescence imaging. Cells were fixed in methanol and incubated 1 h in antibody against a-tubulin (Sigma-Aldrich) or GFP (Santa Cruz Figure 1 . The intracellular domain of HER4, s80 HER4 , inhibits growth via G 2 -M delay. A, A.1, Western blot analysis to detect phosphorylated tyrosine (P-Tyr ) residues or total HER4 expression in HER4 immunoprecipitates from membrane, cytoplasmic, or nuclear extracts from HeLa-rtTA cells expressing pLXSN, pLXSN-HER4,  pLXSN-HER4   KD   , or pLXSN-HER4 VA . Serum-starved cells were treated F HRG (2 h) before separation into cellular compartments using biochemical methods. Left, molecular weights. A.2, cells grown in serum-free medium F HRG (48 h) were stained with propidium iodide and >10,000 cells were analyzed by flow cytometry. Representative histograms. B, Western blot analysis to detect GFP in HER4 immunoprecipitates (IP ) from HeLa-s80 and HeLa-s80 KD cells cultured + tetracycline (TET ) for 0 to 24 h. IB, immunoblot. C, C.1, representative histograms of HeLa-pcDNA4 and HeLa-s80 cells grown in serum-free medium F tetracycline (48 h) and stained with propidium iodide and >10,000 cells were analyzed by flow cytometry. *, P < 0.002, Student's unpaired t test. C.2, equal numbers of HeLa-pcDNA4, HeLa-s80, and HeLa-s80 KD cells were plated, allowed to attach (24 h), and then treated for 0 or 96 h F tetracycline in serum-free medium. D, equal numbers of HC11, MCF-10A, or MDA-453 cells expressing GFP-tagged s80 or GFP were plated, allowed to attach (24 h), and then cultured for 0 or 96 h in serum-free medium. Each sample was counted in duplicate; each experiment was done in triplicate. Columns, average number of cells; bars, SD. **, P < 0.01, Student's unpaired t test; @, P < 0.02, Student's unpaired t test;^, P < 0.01, Student's unpaired t test. Bottom, Western blot analysis to detect s80 HER4 in cell lysates.
Biotechnology) and then with rhodamine-conjugated goat anti-mouse and Alexa Fluor 488-conjugated goat anti-rabbit antibody (Molecular Probes). Samples were mounted with Vectastain 4 ¶,6-diamidino-2-phenylindole (DAPI) mounting medium (Vector Laboratories). Cell growth assays. Cells (0.1 Â 10 6 ) were plated in 15-cm dishes at day 0 F HRG or tetracycline. Three plates per cell type per condition were collected by trypsinization and manually counted daily in duplicate.
Cell cycle analysis. Cells were collected by trypsinization, fixed in 75% methanol, and then stained with propidium iodide + RNase A (Becton Dickinson). Stained nuclei per sample (10,000) were analyzed in a FACSCalibur flow cytometer (Becton Dickinson). DNA histograms were modeled using ModFit LT software (Verity).
Tumor studies. HC11P cells were generated by transfection of pcDNA3-PyVmT (a gift from Dr. Bruce Cuevos, University of North Carolina, Chapel Hill, NC) followed by selection with hygromycin. Antibiotic-resistant clones were individually analyzed for polyomavirus middle T antigen (PyVmT) expression by Northern blot analysis. A single clone, HC11P, was transfected with pcDNA4, pcDNA4-s80, pcDNA4-s80 KD , and pcDNA4-s80 db , selected with zeocin, clonally expanded, and analyzed for expression. Pooled clones of cells (1 Â 10 6 ) were injected into the inguinal mammary glands of 6-week-old BALB/c female mice using sterile surgical procedures. Mice were examined weekly by palpation. Mice were sacrificed 15 weeks after tumor injection, and tumor-bearing mammary glands were immediately fixed in formalin, paraffin embedded, and sectioned for analysis.
Results
HRG-induced cleavage of HER4 to produce s80
HER4 is required for HER4-mediated G 2 -M delay of HeLa cells. Ligand-mediated HER4 activation is known to result in HER4 cleavage to produce the liberated 80-kDa intracellular domain. Production of s80 HER4 was shown in HeLa-rtTA cells (that do not express detectable endogenous HER4) transfected with a cDNA construct encoding wild-type human HER4 (JMa/Cyt1 splice isoform). Treatment of HeLa-HER4 cells with 10 ng/mL HRG for 2 h was followed by separation of the cells into membrane, cytoplasmic, and nuclear compartments. HER4 immunoprecipitates were analyzed for tyrosine phosphorylation and total HER4 expression by Western blot analysis. HER4 immunoprecipitation from HRG-treated cells revealed ligand-dependent HER4 tyrosine phosphorylation at 180 kDa in membranes from HeLa-HER4 cells and the appearance of an 80-kDa tyrosine-phosphorylated HER4 product in membrane, cytoplasmic, and nuclear extracts but not in untreated, serum-starved HeLa-HER4 cells (Fig. 1A.1 ). We also examined the effects of HRG on cells expressing kinasedead human HER4 (HER4 KD ) and on cells expressing a HER4 mutant (V675 to A), which abolishes the HER4 intramembranous, g-secretase cleavage site (referred to herein as HER4 VA ; ref. 37 ). Tyrosine phosphorylation of membrane-bound, full-length HER4 VA was detected in HRG-treated HeLa-HER4 VA cells, as was a membrane-tethered 80-kDa HER4 VA product, although to a lesser extent than what was observed for HRG-treated HeLa-HER4 cells. The 80-kDa HER4
VA product was not detected in cytoplasmic or nuclear extracts from HRG-treated HeLa-HER4 VA cells, suggesting that the final intramembranous cleavage of HER4 VA was not achieved, thus preventing the release of soluble s80
HER4
. As previously shown, kinase-dead HER4 KD was not phosphorylated and did not form the 80-kDa cleavage product, suggesting that kinase activity of HER4 is required to initiate HER4 cleavage ( Fig. 1A.1 ).
HER4 is required for HRG-mediated growth inhibition and G 2 -M delay in several breast cancer cells (9, 21) . HeLa-pLXSN, HeLa-HER4, HeLa-HER4 KD , and HeLa-HER4 VA cells were treated F HRG for 48 h in serum-free medium to examine the effects of HRG on cell cycle distribution. Whereas exogenous HER4 expression conferred HRG-mediated G 2 -M delay to HeLa cells, expression of HER4 KD and HER4 VA did not allow for any observable HRGmediated G 2 -M delay ( Fig. 1A. 2), suggesting that kinase activity and s80 HER4 production are required for HRG-mediated cell cycle delay in HeLa-rtTA cells.
Expression of s80 HER4 decreases growth and G 2 -M transit of HeLa and breast cancer cells. We stably introduced into HeLartTA cells a tetracycline-inducible pcDNA4 construct expressing the Cyt1 isoform of s80 HER4 or kinase-dead s80 KD , each tagged at the NH 2 terminus with GFP. Treatment of cells with tetracycline Figure 2 . Cell cycle-specific expression of s80 HER4 . A, HeLA-s80 cells were treated + tetracycline for 24 h to induce GFP-s80 HER4 followed by 16 h of treatment + tetracycline in serum-free (SF ) medium, + tetracycline/ (HU ) hydroxyurea, + tetracycline/+ olomoucine (OLO), or + tetracycline/+ nocodazole (NOC ). Where indicated, cells were released into serum-containing medium for 15 min. Whole-cell extracts were examined by HER4 immunoprecipitation and GFP immunoblot. B, immunocytofluorescence of HeLa-s80 cells cultured + tetracycline (48 h). Cells were dual stained for GFP and a-tubulin. Right, DAPI images.
induced target gene expression within 6 to 12 h, reaching a maximum by 24 h (Fig. 1B) . Induction of GFP-s80 HER4 expression increased the proportion of HeLa cells with 4N DNA compared with HeLa-pcDNA4 control cells treated with tetracycline ( Fig. 1C.1 than in these cells expressing GFP alone (Fig. 1D) . Taken together, these data suggest that s80 HER4 production is both necessary and sufficient to decrease growth of HeLa and breast-derived cells.
Expression of GFP-s80 HER4 is regulated with the cell cycle. Expression of GFP-s80 HER4 was induced with tetracycline for 24 h. We then analyzed expression of GFP-s80 HER4 in extracts from cells that were synchronized for 16 h in G 1 with serum-free medium, in S phase with hydroxyurea, at the G 2 -M transition with olomoucine, or in mitosis with nocodazole. Cells were then released from synchronization by feeding the cells with serum-containing medium, or in the case of nocodazole synchronization, the cells were collected by shake off and then resuspended and plated in medium with serum. Although expression of GFP-s80 HER4 was detected in randomly cycling cells and in cells released into G 1 , S, and G 2 , we found that, 15 min after release of cells into mitosis, GFP-s80 HER4 expression was undetectable ( Fig. 2A) . To further examine the expression of s80 HER4 during mitosis, we used immunofluorescent staining of randomly cycling, tetracyclineinduced HeLa-s80 cells to detect GFP-s80 and the mitotic spindle protein a-tubulin. Dual immunofluorescence revealed that, of 47 cells harboring a-tubulin-positive mitotic spindles, 0 of 47 cells simultaneously expressed GFP-s80 HER4 (Fig. 2B) . These results suggest that GFP-s80 HER4 expression decreases during mitosis. Degradation of s80 HER4 in mitosis. We synchronized tetracycline-treated HeLa-s80 cells in mitosis with nocodazole for 16 h and then, on release of cells from mitosis, examined GFP-s80 HER4 stability through the cell cycle by treating the cells with cycloheximide to impair new protein synthesis at 0, 2, 4, 8, and 16 h after nocodazole release. Cells were harvested at 15-min intervals following cycloheximide treatment and expression of GFP-s80 HER4 was analyzed. Although GFP-s80 HER4 expression was detected at time (T) = 0, it was undetectable within 15 min of cycloheximide treatment/nocodazole release (Fig. 3A, lanes 1-4) , indicating that s80 HER4 was rapidly degraded on release into mitosis. By 4 and 8 h after nocodazole release, GFP-s80 HER4 showed increasing stability (Fig. 3A , lanes 10 and 14 show GFP-s80 HER4 15 min after release), and GFP-s80 HER4 was stable through 45 min HER4 was analyzed at 15-min intervals beginning at the time of cycloheximide (CHX ) treatment by HER4 immunoprecipitates and GFP immunoblot. B, HeLa-s80 cells were synchronized + hydroxyurea/+ tetracycline (top ) or + nocodazole/+ tetracycline (bottom ) for 16 h and then released + tetracycline at T = 0. Cells were treated + cycloheximide at T = 0 and 2 h. Expression of GFPs80 HER4 was analyzed as described above. C, cells were cultured + nocodazole/+ tetracycline for 16 h, with PS-341 added for the final 4 h. Cells were released + tetracycline/+ PS-341 at T = 0. Cycloheximide was added at T = 0. Expression of GFP-s80 HER4 was analyzed as described above; blots were stripped and then probed for ubiquitin (bottom ). D, HeLa-s80 HER4 cells transfected with 10 nmol siRNA sequences targeting luciferase or APC2 were treated + nocodazole/+ tetracycline for 16 h. Cells were released + tetracycline/+ cycloheximide. Expression of GFP-s80 HER4 and cyclin B was analyzed at 15-min intervals beginning at the time of cycloheximide treatment by immunoblot of anti-HER4 or anti-cyclin B immunoprecipitates using GFP or cyclin B antibodies, respectively. APC2 was analyzed by immunoblot.
when examined 16 h after nocodazole release (Fig. 3A, lanes 17-20) . Although GFP-s80 HER4 was rapidly degraded when cells were released in mitosis, it was highly stable in cells synchronized in S phase with hydroxyurea and then released (Fig. 3B ). This suggests that s80
HER4 is more stable on release from S phase compared with release from mitosis.
The APC/C directs proteasomal degradation of s80 HER4 during mitosis. Tetracycline-treated HeLa-s80 cells were synchronized with nocodazole for 16 h and treated with the proteasome inhibitor PS-341 for the final 4 h of synchronization. Cells were released from nocodazole in the presence of cycloheximide at T = 0, and stability of GFP-s80 HER4 was measured as described above. Inhibition of the proteasome blocked degradation of s80 HER4 through 45 min after release from nocodazole and allowed for the accumulation of ubiquitinated GFP-s80 HER4 (Fig. 3C) , suggesting that s80
HER4 is ubiquitinated during mitosis and degraded by the proteasome.
The APC2 subunit, required for APC/C activity (39, 40) , was knocked down using transfection of siRNAs into HeLa-s80 HER4 cells (Fig. 3D) . Transient transfection of 20 nmol APC2 siRNA (Santa Cruz Biotechnology) impaired expression of APC2 protein in HeLas80 HER4 cells. APC2 siRNA-transfected cells were grown in the presence of tetracycline for 48 h, adding nocodazole to the cells for the final 16 h of culture to synchronize the cells in mitosis. Cells were released from nocodazole and treated with cycloheximide at T = 0. Expression of GFP-s80
HER4 was analyzed at 15-min intervals following nocodazole release/cycloheximide treatment. GFPs80 HER4 was detected through 45 min following nocodazole release in cells lacking APC2 expression. In contrast, cells transfected with a control siRNA sequence showed decreased levels of GFP-s80 HER4 expression 15 min after nocodazole release and did not harbor detectable levels of GFP-s80 HER4 at 30 min following nocodazole release. Similarly, expression of cyclin B, a known target of the APC/C, was stabilized in cells lacking APC2 expression but not in cells transfected with a control siRNA sequence. This suggests that s80 HER4 , like cyclin B, is a target of the APC/C. This represents a novel regulatory mechanism of nuclear signaling for RTKs.
The D-box motif of s80 HER4 is required for its APC/Cmediated degradation. Examination of the intracellular domain amino acid sequence of human HER4 revealed a canonical D-box, a motif found in numerous proteins targeted by the APC/C for mitotic destruction, including cyclin B (Table 1) . Examination of sequences revealed that the D-box present in the HER4 intracellular domain was also seen in HER1/epidermal growth factor receptor (EGFR) but not in HER2 or HER3 (alignment according to ref. 41 ). To test the functionality of this motif, we introduced point mutations into the D-box motif of full-length HER4 and GFP-s80 HER4 to eliminate the RXXLXXXXD consensus sequence, generating HER4 db /s80 db with sequences of AXXAXXXXD (Table 1) . Expression constructs encoding GFP-tagged s80 db were used to generate stable tetracycline-inducible HeLa-rtTA cell lines.
HeLa-s80 HER4 , HeLa-s80 db , and HeLa-s80 KD cells were treated with tetracycline for 24 h to induce expression of GFP-s80 HER4 , GFP-s80 KD , and GFP-s80 db , respectively. Constitutive tyrosine phosphorylation of GFP-s80 HER4 and GFP-s80 db was observed (Fig. 4A.1 ), consistent with a recent report that s80 HER4 is an active tyrosine kinase (42) . Tyrosine phosphorylation of GFP-s80 KD was not observed (Fig. 4A.1 ) as expected. We synchronized tetracyclinetreated HeLa-s80 db cells in mitosis with nocodazole for 16 h and then released the cells in the presence of cycloheximide at T = 0. Expression of GFP-s80 db was analyzed at 15-min intervals following nocodazole release/cycloheximide treatment ( Fig. 4A.2 ). Strong GFP-s80 db expression was detected 45 min following cycloheximide treatment after release into mitosis, unlike GFP-s80 HER4 , which was undetectable within 15 min following cycloheximide treatment and release into mitosis (see Fig. 3A ). Cyclin B was readily degraded on nocodazole release in HeLa-s80 db cells, suggesting that GFP-s80 db did not impair the APC/C or proteasomal machinery ( Fig. 4A.2 ). s80 db impairs growth of HeLa cells. Equal numbers of HeLas80 and HeLa-s80 db cells were plated F tetracycline and counted daily (Fig. 4B) . Uninduced cells proliferated and cell number increased more than 4-fold in 4 days. Tetracycline-treated HeLa-s80 cells were less proliferative and only increased the cell number by 2.2-fold after 4 days in culture. Tetracycline-treated HeLa-s80 db cells were markedly growth inhibited; cell number increased by only 1.4-fold (P = 0.011, compared with tetracycline-treated HeLa-s80 cells; n = 5). Moreover, HeLa-s80 db cells treated with tetracycline for 48 h displayed a dramatic increase in the 4N-containing population compared with uninduced HeLa-s80 db cells (Fig. 4C) .
To examine the progression of HeLa-s80, HeLa-s80 db , and HeLas80 KD cells through the cell cycle over a 24-h period, tetracyclinetreated cells were synchronized in S phase with hydroxyurea and then released into medium + tetracycline at T = 0 h. Cells were collected at 0, 2, 4, 8, 12, and 24 h following hydroxyurea release and analyzed at each time point by flow cytometry to determine the proportion of cells in each phase of the cell cycle. Thus, we were able to observe the progression out of S phase, through G 2 -M, and into G 1 as a function of time. At T = 0 h, all cells harbored DNA content between 2N and 4N, suggesting that hydroxyurea-mediated synchronization in S phase was complete for each cell line (Fig. 4D ). An increase in the amount of 2N-and 4N-containing populations was evident for each cell line by 2 h. However, by 8 (Fig. 5A ), similar to HeLa cells expressing wild-type HER4. This suggests that expression, kinase activity, and liganddependent proteolytic cleavage of HER4 are not impaired by mutation of the D-box. Immunolocalization of HER4 in HRGtreated HeLa-HER4 db cells revealed cells with nuclear HER4 db in the same microscopic field as other cells with strictly cytoplasmic HER4 db similar to full-length, wild-type HER4 (Fig. 5B) . To determine if s80 db derived from full-length HER4 db displays greater stability than wild-type s80 HER4 derived from full-length, wild-type HER4, HeLa-HER4 and HeLa-HER4 db cells were synchronized in , and HeLa-s80 KD cells cultured 24 h + tetracycline. Immunoprecipitates were analyzed for phosphorylated tyrosine or GFP. A.2, HeLa-s80 db cells were cultured + nocodazole/+ tetracycline (16 h). Cells were released + tetracycline/+ cycloheximide at T = 0, and extracts were collected at 15-min intervals. Expression of s80 db and cyclin B was analyzed as described in Fig. 3 . B, equal numbers of cells were plated at day 0 F tetracycline. Cells were counted at 1-d intervals through 4 d. P = 0.011, comparing cell number of HeLa-s80 HER4 + tetracycline at day 4 with cell number of HeLa-s80 db + tetracycline at day 4, n = 5, analyzed in triplicate. C, cell cycle analysis of HeLa-s80 db cells cultured F tetracycline (48 h). Nuclei (>10,000) were analyzed per condition (n = 3). Representative histograms. D, cells were cultured + hydroxyurea/+ tetracycline for 16 h to synchronize in S phase. Cells were released + tetracycline at T = 0 h. Cells were collected at 0, 2, 4, 8, 12, and 24 h following hydroxyurea release. Cells were stained with propidium iodide and analyzed by flow cytometry as described above. mitosis using nocodazole for 16 h and then serum starved in the presence of nocodazole for an additional 16 h. Cells were treated with HRG 1 h before release. Finally, cells were released from nocodazole in the presence of HRG and cycloheximide to examine the stability of proteolytically derived s80 HER4 and s80 db at 15-min intervals. Whereas s80 db was detected through 45 min following release from nocodazole, s80 HER4 was not detected in cells released during mitosis (Fig. 5C) .
Expression of s80 db prevents tumor formation in vivo. Transformation of HC11 cells by overexpression of human ErbB2 confers tumorigenic potential to HC11 cells in vivo (43) . We used a similar approach, transfecting HC11 cells with a cDNA construct encoding the PyVmT. A clonal population of HC11-PyVmT (HC11P) cells was then transfected with pcDNA4-s80 HER4 , pcDNA4-s80 KD , pcDNA4-s80 db , or empty pcDNA4. Cells (1 Â 10 6 ) were injected into the inguinal mammary fat pads of 6-week-old female BALB/c mice. Fifteen weeks following injection, the injected mammary glands were examined histologically. HC11P-pcDNA4 cells formed solid, poorly differentiated tumors (Fig. 6A) . In contrast, tumors expressing s80 HER4 were smaller, harboring numerous differentiated epithelial structures organizationally similar to lobuloalveolar structures often seen in mouse mammary glands during early pregnancy. HC11P-s80 KD cells formed highly proliferative solid tumors resembling tumors formed by HC11P-pcDNA4 cells. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) revealed that HC11P-s80 KD and HC11P-pcDNA4 tumors harbored similar ratios of PCNA + cells (P = 0.166, Student's unpaired t test; n = 5 tumors and 3 fields per tumor; Fig. 6B ), whereas HC11P-s80 tumors exhibited 3-fold fewer PCNA + cells than vector controls (P < 0.001). Implanted HC11P-s80 db cells formed large cystic structures of single epithelial layers surrounding large lumens filled with eosinophilic proteins, suggesting a degree of lactogenic differentiation (Fig. 6A) . These did not seem to have malignant elements, and these structures exhibited the lowest percentage of PCNA + cells (9%; Fig. 6B ), with a statistically significant decrease in PCNA staining compared with HC11-s80 tumors (12.5%; P = 0.0371). No statistically significant differences were detected in the rate of cell death between the four groups as measured by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling (TUNEL) analysis (Fig. 6B) . These results suggest that expression of s80 HER4 decreases growth of breast tumors in vivo, and mutation of the s80 HER4 D-box enhances tumor suppression by s80 HER4 , perhaps by increasing the stability of s80
HER4 .
Discussion
Recent evidence shows that ligand-mediated activation of the JMa HER4 isoform results in HER4 cleavage and liberation of the intracellular domain, s80 HER4 , which has the ability to localize to the nucleus. Our studies show the destruction of s80 HER4 during mitosis by the cell cycle machinery, representing a novel regulatory mechanism for a RTK, and may relate directly to the ability of HER4 to slow cell growth by inhibiting progression through G 2 or M.
Many proteins are degraded by the APC/C in a D-boxdependent manner. Of these, most have defined roles in regulating mitotic progression, including cyclin B, polo-like kinase, aurora A, and securin. Inhibition of APC/C-mediated degradation of these proteins results in delayed progression through mitosis. For example, cyclin B1 in mammalian cells is degraded before anaphase (44) and expression of a nondegradable cyclin B1 harboring a mutation within the D-box delayed mitosis in mammalian cells and frog oocytes by blocking the metaphase/ anaphase transition or cell division (45, 46) . Similarly, mutation of the s80 HER4 D-box impaired its destruction and decreased the rate of G 2 -M progression, suggesting that destruction of the intracellular domain of HER4, like cyclin B, may be required for progression through the cell cycle in cells expressing nuclear HER4. The mechanism by which HER4 delays progression through G 2 -M is currently under investigation. However, our results are Figure 5 . Mutation of the D-box within full-length HER4 does not reduce s80 HER4 production but does stabilize s80 HER4 . A, HeLa cells stably transfected with pLXSN-HER4 or pLXSN-HER4 db were serum starved 16 h and then treated + HRG (1 h). HER4 immunoprecipitates were analyzed for total HER4. B, cells were serum starved (16 h) and treated + HRG (1 h). Cells were analyzed for HER4 localization by immunocytofluorescence. Bottom, DAPI staining. N, nuclear localization of HER4; C, cytoplasmic localization of HER4. C, HeLa-HER4 and HeLa-HER4 db cells were cultured in 10% serum + nocodazole (16 h ) and then in serum-free medium + nocodazole (16 h), adding HRG for the final hour. Cells were released into serum-free medium + HRG/+ cycloheximide at T = 0 and harvested at T = 0, 15, 30, and 45 min. HER4 immunoprecipitates were analyzed as described above.
consistent with the idea that the intracellular domain of HER4-Cyt1 may indeed be involved in regulating the G 2 -M transition or progression through early mitosis.
The discovery of ligand-dependent JMa HER4 proteolysis and release of a nuclear-localizing soluble tyrosine kinase has resulted in multiple studies investigating the function of s80 HER4 . We and others have shown s80 HER4 growth-inhibitory action (21, 33, 37) and that HRG-mediated HER4 activity, as well as de novo expression of s80 HER4 , slows the progression of cells through G 2 -M. The data presented herein suggest a physiologic mechanism for the regulation of s80 HER4 by APC-dependent ubiquitination and degradation during M phase.
Other recent reports have suggested specific transcriptional roles for nuclear s80 HER4 complexed with transcription factors or cofactors. These include a positive effect on ER-mediated gene transcription in ER-positive breast cancer cells (47) , on signal transducers and activators of transcription 5A (STAT5A)-dependent gene expression in differentiating mammary epithelial cells, and on repression of astrocyte-specific gene transcription in astrocyte progenitor cells in the developing mouse brain (48) . In these studies, s80
HER4 colocalized in complexes on specific DNA elements [e.g., on the progesterone receptor promoter with the ER or the glial fibrillary acidic protein promoter with TAB2 and N-Cor (47, 48) ]. Additionally, s80
HER4 may enhance transcription factor activity through kinase-mediated phosphorylation of target proteins. For example, s80
HER4 phosphorylates the transcription factor STAT5A and enhances STAT5A-dependent transcription (12, 37) . s80
HER4 also facilitates movement of the transcriptional complex from cytoplasm to nucleus. Whether our postulated functional interaction with G 2 -M checkpoint cell cycle control mechanisms requires transcriptional control at specific promoters or tyrosine phosphorylation of other regulatory elements remains to be determined. It will be of interest to determine whether altering s80 HER4 mitotic destruction via the D-box mutation changes transcriptional modulators to address whether growth inhibition and transcriptional control by s80 HER4 are distinct mechanistically.
The findings reported here may have clinical implications. Most clinical correlative studies of human breast cancer agree that HER4 correlates with positive prognostic indicators. We have shown the HER4 activation (9) or s80 HER4 expression (see Fig. 1 ; ref. 21 ) inhibited breast cancer cell growth by decreasing the progression of cells through G 2 -M (21). Furthermore, we have shown (Fig. 6 ) that s80
HER4 slowed transformed breast cell proliferation when expressed in PyVmT-expressing HC11 cells. Ligand-mediated activation of HER4 results in s80 HER4 release, nuclear-cytoplasmic shuttling, and growth inhibition; interference with proteolytic cleavage (HER4 VA ; see Fig. 1 ) abrogates this action. Thus, s80 HER4 production is an obligatory step for HER4-mediated growth inhibition. Moreover, s80 HER4 expression is sufficient to confer growth inhibition to HeLa cells, or breast cancer cells, in the absence of full-length HER4 or ligand stimulation (21) . The growthinhibitory signal of s80 HER4 was strengthened by D-box mutation. Because the D-box is required for degradation during mitosis, it is possible that s80 HER4 impairs growth of cells by delaying the cell cycle in mitosis such that degradation of s80 HER4 is required for mitotic progression. Although this hypothesis requires further investigation, these data show the potential link between nuclear , or the empty pcDNA4 vector were injected into the inguinal mammary fat pads of female BALB/c mice. Fifteen weeks after implantation of cells, mice were euthanized and the mammary glands were analyzed histologically. Representative images. B, five tumor samples per group were analyzed by immunohistochemistry. PCNA-positive (top ) or TUNEL-positive (bottom ) nuclei were scored in three randomly chosen 400Â fields per tumor section, for a total of 15 fields counted. HC11P-pcDNA4 and HC11P-s80 KD had equivalent percentages of PCNA-positive nuclei (29.4 F 2.2 and 34.1 F 2.9, respectively). HC11P-s80 had a statistically significantly lower percentage of PCNA-positive cells (12.5 F 1.1; P < 0.0001) compared with vector alone, whereas HC11P-s80 db percentage of PCNA-positive cells was the lowest of all groups (9.0 F 2.2) and was also significantly decreased when compared with HC11P-s80 (P < 0.037).
